文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

经皮耳迷走神经刺激治疗轻度认知障碍患者的疗效和安全性:一项双盲随机临床试验。

The efficacy and safety of transcutaneous auricular vagus nerve stimulation in patients with mild cognitive impairment: A double blinded randomized clinical trial.

机构信息

Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, 100700, China.

Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.

出版信息

Brain Stimul. 2022 Nov-Dec;15(6):1405-1414. doi: 10.1016/j.brs.2022.09.003. Epub 2022 Sep 21.


DOI:10.1016/j.brs.2022.09.003
PMID:36150665
Abstract

BACKGROUND: There are 9.9 million new cases of dementia in the world every year. Short-term conversion rate from mild cognitive impairment (MCI) to dementia is between 20% and 40%, but long-term in 5-10 years ranges from 60% to 100%. It is particularly important to prevent or prolong the development of MCI into dementia. Both auriculotherapy and vagus nerve stimulation are effective on improving cognitive functions. However, there is no double blinded randomized clinical trial to support the effectiveness of transcutaneous electrical stimulation of auricular acupoints in patients with MCI. METHODS: This randomized controlled trial involved patients with MCI, aged from 55 to 75 years old. Patients were randomly allocated to transcutaneous auricular vagus nerve stimulation (taVNS) group or sham taVNS group. In the taVNS group, two auricular acupoints were stimulated, including heart (concha, CO) and kidney (CO), which are in the distribution of vagus nerve. While in the sham taVNS group, two other auricular acupoints were stimulated, including elbow (scaphoid fossa, SF) and shoulder (SF), which are out of the distribution of vagus nerve. The primary outcome was the Montreal cognitive assessment-basic, MOCA-B. The secondary outcomes included auditory verbal learning test-HuaShan version (AVLT-H), shape trails test A&B (STT-A&B), animal fluence test (AFT), Boston naming test (BNT), Pittsburgh sleep quality index (PSQI), rapid eye movement sleep behavior disorder screening questionnaire (RBDSQ), Epworth sleepiness scale (ESS) and functional activities questionnaire (FAQ). These outcome measures were taken at baseline, 24 weeks later. RESULTS: After 24 weeks of intervention, the data of 52 patients were intended for analysis. After intervention, there was significant difference in the overall scores of MoCA-B between taVNS group and sham taVNS group (p = 0.033 < 0.05). In taVNS group, compared with before intervention, the overall scores of MOCA-B increased significantly after intervention (p < 0.001). As for N5 and N7, the two sub-indicators of AVLT-H, in taVNS group, compared with before intervention, both N5 and N7 increased significantly after intervention (both ps < 0.001). As for STTB, in taVNS group, compared with before intervention, STTB was significantly reduced after intervention (p = 0.016). For BNT, in taVNS group, compared with before intervention, BNT increased significantly after intervention (p < 0.001). In taVNS group, compared with before intervention, PSQI, RBDSQ, ESS and FAQ decreased significantly after intervention (p = 0.002, 0.025, <0.001, 0.006 respectively). 1 patient with a history of tympanic membrane perforation in taVNS group was reported with mild adverse reactions which disappeared a week after termination of taVNS. The intervention of taVNS is effective on increasing the overall scores of MoCA-B, N5 and N7. CONCLUSION: The clinical trial demonstrated that taVNS can improve cognitive performance in patients with MCI. This inexpensive, effective and innovative method can be recommended as a therapy for more patients with MCI in the prevention or prolonging of its development into dementia, but it is still required to be further investigated. TRIAL REGISTRATION: http://www.chictr.org.cn. (ID: ChiCTR2000038868).

摘要

背景:全球每年新增痴呆症病例 990 万例。从轻度认知障碍(MCI)到痴呆的短期转化率在 20%至 40%之间,但在 5 至 10 年内的长期转化率在 60%至 100%之间。特别重要的是预防或延长 MCI 向痴呆的发展。耳穴疗法和迷走神经刺激都对改善认知功能有效。然而,目前尚无双盲随机临床试验支持经皮耳迷走神经刺激(taVNS)治疗 MCI 患者的有效性。

方法:本随机对照试验纳入了 55 至 75 岁的 MCI 患者。患者被随机分配至 taVNS 组或假 taVNS 组。在 taVNS 组中,刺激两个耳穴,包括心脏(耳甲腔,CO)和肾脏(CO),这些穴位都在迷走神经的分布区域内。而在假 taVNS 组中,刺激另外两个耳穴,包括肘(舟状窝,SF)和肩(SF),这些穴位都不在迷走神经的分布区域内。主要结局指标是蒙特利尔认知评估-基础版,MOCA-B。次要结局指标包括听觉词语学习测试-华山版(AVLT-H)、形状追踪测试 A&B(STT-A&B)、动物流畅性测试(AFT)、波士顿命名测试(BNT)、匹兹堡睡眠质量指数(PSQI)、快速眼动睡眠行为障碍筛查问卷(RBDSQ)、Epworth 嗜睡量表(ESS)和功能活动问卷(FAQ)。这些结果测量在基线和 24 周后进行。

结果:干预 24 周后,52 名患者的数据用于分析。干预后,taVNS 组和假 taVNS 组的 MoCA-B 总分有显著差异(p=0.033<0.05)。在 taVNS 组中,与干预前相比,干预后 MoCA-B 的总分显著增加(p<0.001)。对于 AVLT-H 的两个亚指标 N5 和 N7,在 taVNS 组中,与干预前相比,N5 和 N7 在干预后均显著增加(均 p<0.001)。对于 STTB,在 taVNS 组中,与干预前相比,STTB 在干预后显著减少(p=0.016)。对于 BNT,在 taVNS 组中,与干预前相比,BNT 在干预后显著增加(p<0.001)。在 taVNS 组中,与干预前相比,PSQI、RBDSQ、ESS 和 FAQ 在干预后均显著下降(p=0.002、0.025、<0.001、0.006)。一名 taVNS 组中有鼓膜穿孔史的患者报告出现轻度不良反应,该反应在 taVNS 终止一周后消失。taVNS 的干预对增加 MoCA-B、N5 和 N7 的总分有效。

结论:临床试验表明,taVNS 可以改善 MCI 患者的认知表现。这种廉价、有效和创新的方法可以推荐给更多的 MCI 患者,以预防或延长其发展为痴呆,但仍需要进一步研究。

试验注册:http://www.chictr.org.cn。(注册号:ChiCTR2000038868)。

相似文献

[1]
The efficacy and safety of transcutaneous auricular vagus nerve stimulation in patients with mild cognitive impairment: A double blinded randomized clinical trial.

Brain Stimul. 2022

[2]
Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Insomnia Disorder: A Randomized Clinical Trial.

JAMA Netw Open. 2024-12-2

[3]
Influence of a 2-week transcutaneous auricular vagus nerve stimulation on memory: findings from a randomized placebo controlled trial in non-clinical adults.

Clin Auton Res. 2024-8

[4]
The combined effect of transcutaneous electrical nerve stimulation and transcutaneous auricular vagus nerve stimulation on pressure and heat pain thresholds in pain-free subjects: a randomized cross-over trial.

Trials. 2024-7-31

[5]
Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study.

J Affect Disord. 2016-5

[6]
Effectiveness and safety of transcutaneous auricular vagus nerve stimulation for depression in patients with epilepsy.

Epilepsy Behav. 2025-2

[7]
Transcutaneous auricular vagus nerve stimulators: a review of past, present, and future devices.

Expert Rev Med Devices. 2022-1

[8]
The efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with minimally conscious state: a sham-controlled randomized double-blind clinical trial.

Front Neurosci. 2023-12-14

[9]
Safety and effectiveness of transcutaneous auricular vagus nerve stimulation on patients with depersonalization-derealization disorder: study protocol for a randomized controlled trial.

Trials. 2024-12-5

[10]
Transcutaneous electrical stimulation at auricular acupoints innervated by auricular branch of vagus nerve pairing tone for tinnitus: study protocol for a randomized controlled clinical trial.

Trials. 2015-3-19

引用本文的文献

[1]
Feasibility of vagus nerve modulation (VNMM/taVNS) in cognitive-swallowing dual-task paradigms: a fNIRS pilot study.

Front Neurosci. 2025-8-11

[2]
Longitudinal relationships between changes in post-COVID mental fatigue and neuropsychiatric symptoms across distinct recovery trajectories.

Inflammopharmacology. 2025-8-11

[3]
Research Progress of Acupuncture in Disease Management through Autonomic Nerve System Modulation.

Chin J Integr Med. 2025-7-25

[4]
A vagal route to memory: evidence from invasive and non-invasive electrical vagus nerve stimulation studies and areas for future clinical application.

Front Hum Neurosci. 2025-7-8

[5]
Transcutaneous auricular vagus nerve stimulation enhanced working memory in older adults with age-related hearing loss.

Sci Rep. 2025-7-22

[6]
Pharmacological and Non-Pharmacological Interventions to Improve Sleep in People with Cognitive Impairment: A Systematic Review and Meta-Analysis.

Int J Environ Res Public Health. 2025-6-18

[7]
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia Disorder: A Narrative Review of Effectiveness, Mechanisms and Recommendations for Clinical Practice.

Nat Sci Sleep. 2025-6-13

[8]
Effect of transcranial magnetic stimulation combined with transcutaneous auricular vagus nerve stimulation on mild cognitive impairment: a study protocol for a randomized controlled trial.

Front Aging Neurosci. 2025-5-30

[9]
Transcutaneous auricular vagus nerve stimulation prevents postoperative delirium in elderly patients (VNSTAR): protocol for a multicentre, randomised controlled trial.

BMJ Open. 2025-5-30

[10]
Vibrotactile auricular vagus nerve stimulation alters limbic system connectivity in humans: A pilot study.

PLoS One. 2025-5-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索